3 results
Approved WMORecruiting
To evaluate, in patients with end stage knee osteoarthritis, the in vivo disease (tissue structure) modifying activity of celecoxib, as a selective COX-2 inhibitor, in addition to its inflammation regulatory properties, compared to naproxen as a…
Approved WMOPending
The objective of this study is to achieve better adherence to fluid restriction by providing insight to patient*s drinking behavior, by using the MySleeve device (MS).
Approved WMOPending
Phase 1 - Primary Objective• To determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of single-agent MCLA-129 in patients with NSCLC, GC/GEJ adenocarcinoma, HNSCC or ESCC, with disease progression after prior therapy for…